Systematic Optimization of the iMALDI Workflow for the Robust and Straightforward Quantification of Signaling Proteins in Cancer Cells-Reference-Cited by-同舟云学术

Systematic Optimization of the iMALDI Workflow for the Robust and Straightforward Quantification of Signaling Proteins in Cancer Cells

Published:2020-08-09 Issue:5 Volume:14 Page:2000034
ISSN:1862-8346
Container-title:PROTEOMICS – Clinical Applications
language:en
Short-container-title:Prot. Clin. Appl.

Author:

Froehlich Bjoern C.¹²,Popp Robert¹,Sobsey Constance A.³,Ibrahim Sahar³,LeBlanc Andre M.³,Mohammed Yassene¹⁴⁵,Aguilar‐Mahecha Adriana⁶,Poetz Oliver⁷⁸,Chen Michael X.⁹,Spatz Alan⁶,Basik Mark⁶,Batist Gerald⁶¹⁰,Zahedi René P.³⁵,Borchers Christoph H.¹³¹⁰⁵^ORCID

Affiliation:

1. University of Victoria‐Genome BC Proteomics Centre University of Victoria Victoria BC V8Z 7E8 Canada

2. Department of Biochemistry and Microbiology University of Victoria Victoria BC V8P 5C2 Canada

3. Segal Cancer Proteomics Centre Lady Davis Institute Jewish General Hospital McGill University Montreal QC H3T1E2 Canada

4. Center for Proteomics and Metabolomics Leiden University Medical Center Leiden 2333 ZA The Netherlands

5. Center for Computational and Data‐Intensive Science and Engineering Skolkovo Institute of Science and Technology Moscow 121205 Russia

6. Segal Cancer Centre Lady Davis Institute Jewish General Hospital McGill University Montreal QC H3T1E2 Canada

7. NMI Natural and Medical Sciences Institute University of Tuebingen Reutlingen 72770 Germany

8. SIGNATOPE GmbH Reutlingen 72770 Germany

9. Department of Pathology and Laboratory Medicine Faculty of Medicine University of British Columbia Vancouver Canada

10. Gerald Bronfman Department of Oncology Jewish General Hospital McGill University Montreal QC H4A3T2 Canada

Funder

Leading Edge Endowment Fund

Genome British Columbia

Genome Canada

Terry Fox Research Institute

Publisher

Wiley

Subject

Clinical Biochemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/prca.202000034

Reference34 articles.

1. Can LC and LC-MS ever replace immunoassays?

2. Pragmatic issues in biomarker evaluation for targeted therapies in cancer

3. Immunohistochemistry as an Important Tool in Biomarkers Detection and Clinical Practice

4. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry

5. Garbage in, garbage out: A critical evaluation of strategies used for validation of immunohistochemical biomarkers

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prospective on Imaging Mass Spectrometry in Clinical Diagnostics;Molecular & Cellular Proteomics;2023-09

2. Accelerating Drug Discovery with Ultrahigh‐Throughput MALDI‐TOF MS;High‐Throughput Mass Spectrometry in Drug Discovery;2023-06-30

3. Immuno-MALDI-MS for Accurate Quantitation of Targeted Peptides from Volume-Restricted Samples;Methods in Molecular Biology;2022

4. Precise Quantitation of PTEN by Immuno-MRM: A Tool To Resolve the Breast Cancer Biomarker Controversy;Analytical Chemistry;2021-07-29

5. A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110α in cell lines and tumor tissues;The Analyst;2021